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CD103+ dendritic cells (DCs) have been shown to play a crucial role in the pathogen-
esis of inflammatory bowel diseases (IBDs) through educating regulatory T (Treg) cells 
differentiation. However, the mechanism of CD103+ DCs subsets differentiation remains 
elusive. Interleukin (IL)-4 is a pleiotropic cytokine that is upregulated in certain types of 
inflammation, including IBDs and especially ulcerative colitis. However, the precise role of 
IL-4 in the differentiation of CD103+ DCs subpopulation remains unknown. In this study, 
we observed a repressive role of IL-4 on the CD103+ DCs differentiation in both mouse 
and human. High-dose IL-4 inhibited the CD103+ DC differentiation. In comparison to 
CD103− DCs, CD103+ DCs expressed high levels of the co-stimulatory molecules and 
indoleamine 2,3-dioxygenase (IDO). Interestingly, IL-4 diminished IDO expression on 
DCs in a dose-dependent manner. Besides, high-dose IL-4-induced bone marrow-de-
rived DCs, and monocyte-derived DCs revealed mature DCs profiles, characterized by 
increased co-stimulatory molecules and decreased pinocytotic function. Furthermore, 
DCs generated under low concentrations of IL-4 favored Treg cells differentiation, which 
depend on IDO produced by CD103+ DCs. Consistently, IL-4 also reduced the frequency 
of CD103+ DC in  vivo. Thus, we here demonstrated that the cytokine IL-4 involved 
in certain types of inflammatory diseases by orchestrating the functional phenotype of 
CD103+ DCs subsets.
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inTrODUcTiOn
Dendritic cells (DCs) is well known as the professional antigen-presenting cells, uptaking and 
processing pathogenic substance, and presenting the antigen to T cells through peptide–MHC 
complex (1). In addition to antigens presentation, DCs also play a crucial role in regulating immune 
response by the co-stimulatory molecules interaction, which provides the second signal in the 
process of T cell activation and proliferation (2). A number of studies have shown that inhibition or 
depletion of costimulatory molecules on DCs can improve activity of inflammatory diseases (3–6). 
Beyond that, there are increasing evidences indicating that DCs also have the capability to induce 
regulatory T (Treg) cells differentiation, which harness the immune homeostasis (7, 8).
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Interleukin (IL)-4, the best-characterized member of the 
type 2 immune response cytokines, was produced by various 
types of cells including CD4+ T cells, natural killer T cells, 
eosinophils, and activated mast cells (9). In the meantime, 
the function of IL-4 is not yet fully known as the extremely 
broad distribution of IL-4 receptors (10). Previous studies have 
shown that IL-4 is the key pro-inflammatory cytokine in the 
pathological progression of atopic dermatitis, allergic rhinitis, 
COPD, and cancer (11). Besides, IL-4 has also been implicated 
in inflammatory bowel diseases (IBDs) (12, 13). Numerous 
studies have shown that the alteration of T cell polarization 
could ameliorate the development of disease. It has previously 
been demonstrated that the development of atherosclerosis and 
allograft rejection, resulting from Th1 immune response, can 
be reduced by promoting Th2 differentiation (14). However, 
the abnormally upregulated Th1 and Th2 immune responses 
can be observed simultaneously in IBDs (12, 15). Until now, 
the mechanism in this immune dysfunction remains elusive. 
Recently, it has been shown that the presence of IL-4 in the 
initial DCs activation could lead to a dominant Th1 immune 
response, which had a protective effect in Leishmania-infected 
mice (16). In addition, neutralization of IL-4 abrogated IL-12 
secretion in a coculture system of human DCs and Th2 cell 
(17). Furthermore, high IL-12 and low IL-10 expressions were 
observed in DCs generated under high concentrations of IL-4 
(18). The DCs function altered by IL-4 might explain the mixed 
Th1/Th2 immune response in IBDs.
CD103+ DCs play a crucial role in alleviating the pathological 
progression of IBDs through promoting the de novo generation of 
Treg cells by a indoleamine 2,3-dioxygenase (IDO) mechanism 
(19, 20). IDO is a cytoplasmic rate-limiting enzyme involved in 
the catabolism and utilization of tryptophan, which converts 
tryptophan into N-formylkynurenine and subsequently kynure-
nine (21). Recent studies revealed that IDO produced by DCs 
play a critical role in immune tolerance (22, 23). Our previous 
study also demonstrated that the protective effect of IL-33 is 
predominantly dependent on Treg cell expansion, which was 
closely associated with upregulation of CD103+IDO+ DCs 
(24). Epithelium cell-derived TGF-β and retinoic acid (RA) were 
found to be required for CD103+ DC tolerogenic phenotype 
conversion, and epithelium cell from IBDs patients showed an 
impaired function in CD103+ DC conversion (20), which result 
in a diminishment of CD103+ DCs in IBDs (25, 26). Although 
abnormalities in both Th1 and Th2 immune responses were 
detected in ulcerative colitis (UC) patients, the Th2 immune 
response is considered to play a predominant role (15). However, 
very little is known about the exact role of Th2 immune response 
in the DCs conditioning during the development of UC. Here, we 
presented evidence that IL-4 revealed suppressive role on CD103+ 
DCs conversion. Under high IL-4 circumstance, diminishment of 
CD103+ DCs was observed in mice bone marrow-derived DCs 
(BMDCs) and human monocyte-derived DCs (MoDCs), which 
also showed a weaken potency to simulate Treg cells differentia-
tion. Thus, in addition to impaired intestinal epithelium function 
in CD103+ DCs conversion, the inflammatory IL-4 also inhibits 
CD103+ DCs induction, which retard Treg cells differentiation 
and exacerbate the progress of disease.
MaTerials anD MeThODs
animals and human subjects
Female C57BL/6 mice of 6–8  weeks old were purchased from 
the Animal Center of Xiamen University (Fujian, China). The 
mice were housed in the specific pathogen-free facility at the 
Animal Center of Xiamen University for at least 1 week before 
inclusion in experiments. All experimental procedures involving 
mice were approved by the Animal Care and Use Committee 
of Xiamen University and were carried out in accordance with 
the recommendations of Animal Care and Use Committee of 
Xiamen University. Written informed consent was obtained from 
healthy volunteers (n = 10) in accordance with the Declaration 
of Helsinki. The study protocol was approved by the Ethics 
Committee, Tongji Medical College, Huazhong University of 
Science and Technology. The methods were carried out in accord-
ance with the approved guidelines.
induction of colitis
Dextran sulfate sodium (DSS)-induced colitis was induced in 
C57BL/6 mice as described elsewhere (27). Briefly, the mice were 
fed DSS (mol wt. ~40,000; Sigma) 2% (wt/vol) dissolved in sterile 
distilled water for 7 days, followed by a period of 10 days of water 
without DSS. Mice received four cycles of DSS treatment, and 
animals were sacrificed. The serum and mesenteric lymph nodes 
were harvested and analyzed.
reagents
All recombinant cytokines in in vitro experiments were obtained 
from Peprotech (London, UK). The antibodies in this study 
were purchased from commercial companies. Anti-mouse CD4, 
anti-mouse IFN-γ, anti-mouse CD25, anti-mouse Foxp3, anti-
mouse CD11c, anti-mouse CD80, anti-mouse CD86, anti-mouse 
MHC-II, anti-mouse CD103, anti-human CD4, anti-human IFN-
γ, anti-human CD25, anti-human Foxp3, anti-human CD11c, 
anti-human CD80, anti-human CD86, anti-human CD83, and 
anti-human CD103 were obtained from ebioscience (CA, USA). 
Anti-mouse IDO and anti-human IDO were purchased from 
Biolegend (CA, USA) and R&D (MN, USA), respectively.
Mouse BMDcs and human MoDcs 
generation
Bone marrow-derived DCs (BMDCs) were generated from the 
mice bone marrow cells as described previously (28). Briefly, 
BMDCs were propagated from C57BL/6 mouse at 5 × 105/ml cells 
in the presence of GM-CSF (10 ng/ml) and various concentra-
tion of IL-4 (2, 5, and 10  ng/ml). Half of the supernatant was 
replaced by same volume of fresh medium containing amount 
of GM-CSF and IL-4 at days 3 and 5. BMDCs were harvested 
at day 7 for further study. Peripheral blood samples were col-
lected in anticoagulant tubes from healthy volunteers, and then 
peripheral blood mononuclear cells (PBMCs) were isolated 
by standard Ficoll-Hypaque density-gradient centrifugation. 
CD14+ monocytes were purified from PBMCs using positive 
selection with CD14+ Cell Isolation Kit human (Miltenyi Biotec, 
Bergisch Gladbach, Germany). The purity of T cells was >95% as 
FigUre 1 | no difference in cD11c+ dendritic cells (Dcs) 
differentiation from precursor cells by various interleukin (il)-4 
concentrations. To determine the different dose of IL-4 in bone marrow-
derived DCs (BMDCs) and monocyte-derived DCs (MoDCs) differentiation, 
BMDCs and MoDCs were propagated in various IL-4 concentrations 
(nanograms per milliliter) as described in Section “Materials and Methods.” 
After 7 days of BMDCs and 6 days of MoDCs culture, the cells were 
harvested for CD11c staining, which were analyzed by flow cytometry. The 
CD11c+ DC were gated for analyzing. Data are representative of three 
independent experiments.
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determined using flow cytometry. MoDCs were propagated from 
CD14+ monocytes under GM-CSF (50  ng/ml) and at various 
concentration of IL-4 (5, 10, and ng/ml). MoDCs were collected 
after 6 days of culture.
T cells and Dcs coculture
Naïve CD4+ T cells were isolated from splenic cells of normal mice 
and PBMCs of healthy volunteers by naïve CD4+ T cells negative 
selection (Miltenyi Biotech, Bergisch Gladbach, Germany). Then 
the naïve CD4+ T cells were labeled with CFSE and then were 
cocultured with BMDCs or MoDC. A soluble anti-mouse CD3 or 
anti-human CD3 (0.5 μg/ml) antibody was added to the T cells/
DCs cultural medium. The cells and supernatants were harvested 
after 5 days and followed by proliferation assay by flow cytometry. 
The Th1 and Treg cells differentiation were analyzed by intracel-
lular flow cytometry analysis. The 1-MT (25 μM) purchased from 
Sigma-Aldrich (Shanghai, China) was added to some culture 
medium for inhibiting the IDO activity. CD103− DCs were 
isolated from DCs generated under low concentration of IL-4 by 
negative magnetic beads by the following steps. Biotin-conjugated 
anti-CD103 antibody was used, then anti-biotin-beads (Miltenyi 
Biotech, Bergisch Gladbach, Germany) were performed in 
accordance with manufactory instructions.
Pinocytosis assay
The pinocytotic activities of BMDCs and MoDC were measured 
as described previously (29). Briefly, BMDCs and MoDCs 
(2 × 105/ml) were incubated with FITC-dextran (1,000 μg/ml) 
(Sigma-Aldrich, Shanghai, China) for 3  h at 37°C, and then 
the DCs were washed twice with PBS. Cells were collected and 
analyzed by flow cytometry on Coulter Beckman. The mean 
fluorescence intensity of cells incubated with FITC-dextran at 
4°C was set as a fluorescence background.
Flow cytometry
After propagation, the BMDCs and MoDCs were collected for 
surface co-stimulatory molecules staining. The IDO staining was 
performed after DCs treated by Fix/Perm Buffer Set (ebioscience, 
CA, USA). For cytokines intracellular staining, the cells were 
obtained from the coculture medium and were stimulated with 
20 ng/ml PMA and 1 μg/ml ionomycin (Sigma-Aldrich, Shanghai, 
China) plus 2 μm of Monesin (Sigma-Aldrich, Shanghai, China) 
for 4  h following fluorescence-conjugated anti-CD4 antibody 
staining. IFN-γ and Foxp3 staining was performed in accordance 
with the manufacturer’s instructions (ebioscience, CA, USA).
elisa assay
Blood samples were collected by cardiac puncture and placed 
at room temperature for 30  min before centrifugation. The 
serum was stored at −80°C until analyzed. The levels of IL-4 
were determined by ELISA kits (ebioscience) according to the 
manufacturer’s instructions.
Western Blots assay
Total proteins extracted from BMDCs or MoDCs were performed 
to immunoblot assay conducted as described previously (24). The 
primary antibody anti-IDO (Abcam, MA, USA) and anti-β-actin 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used 
to probe the blots. After incubating with secondary antibody-
conjugated horseradish peroxidase, the immunoreactivity was 
detected by an ECL system (Thermofisher, MA, USA).
statistical analysis
All data were analyzed in GraphPad Prism5. The data are pre-
sented as means ± SD. Statistical differences were determined by 
Student’s t-test. Two-sided p < 0.05 was considered as significant.
resUlTs
high concentration of il-4 Promotes a 
Mature Dcs Phenotype from Precursor 
cells
Th2 immune response plays a crucial role in the pathogenesis 
of many diseases. It is well known that IL-4, the core cytokine 
in Th2 immunity, is essential for DCs differentiation. To mimic 
the inflammatory milieu, different concentrations of IL-4 were 
used in these experiments. There were no significant differences 
in the yield of BMDCs and MoDCs generation (Figure  1). In 
comparison to DCs generated under high IL-4 concentrations, 
DCs generated from low IL-4 concentrations displayed an 
immature phenotype. Co-stimulatory molecules on BMDCs and 
MoDCs were markedly higher in high-dose group, when com-
pared with low dose of IL-4 treatment (Figures 2A,B; Table 1). 
Furthermore, under the condition of low IL-4 concentration, the 
BMDCs and MoDCs exhibited an increased pinocytotic ability 
FigUre 3 | interleukin (il)-4 inhibits indoleamine 2,3-dioxygenase 
(iDO) expression during dendritic cells differentiation. Bone marrow-
derived DCs (BMDCs) were propagated from bone marrow cells in GM-CSF 
(10 ng/ml) and different dose of IL-4 (2, 5, and 10 ng/ml) until day 7. 
Monocyte-derived DCs (MoDCs) were generated from CD14+ monocytes in 
GM-CSF (50 ng/ml) and various dose of IL-4 (5, 10, and 20 ng/ml) until day 
6. After differentiation, total protein from BMDCs and MoDCs were extracted 
and subjected to assess IDO expression by immunoblot. All data are 
representative of one of the three independent experiments.
TaBle 1 | analysis of markers expression of dendritic cells (Dcs) 
generated under various concentration of interleukin (il)-4.
Mean fluorescence intensity (MFi)
Monocyte-
derived Dcs 
(MoDcs) (ng/ml)
cD83 cD86 cD80 FiTc-dextran
5 5.97 ± 0.49 135.7 ± 18 41.9 ± 8.3 1,205.3 ± 11.0
10 6.93 ± 0.47a 175.0 ± 23.9a 38.7 ± 4.6 708.3 ± 17.5b
20 9.47 ± 0.75b 337.3 ± 53.4b 65.6 ± 8.3a 583.6 ± 4b
Bone marrow-
derived Dcs 
(BMDcs) (ng/ml)
Mhc-ii cD86 cD80 FiTc-dextran
2 277.3 ± 22.5 44.6 ± 0.7 68.2 ± 4.9 388 ± 14.6
5 375.7 ± 63.5 66.3 ± 1.5a 62.6 ± 4.5 348.2 ± 10
10 478.7 ± 17.8b 84.9 ± 2.6b 70.2 ± 1.0 308 ± 14.8b
The BMDCs and MoDCs were generated under GM-CSF and at different 
concentrations of IL-4 as indicated, which was detailed in Figure 2. MFI of 
costimulatory molecules was obtained by flow cytometry analysis. The FITC-dextran by 
DCs pinocytosis was also analyzed by flow cytometry and present as MFI. Data from 
three independent experiments are presented as mean ± SD. The low concentration of 
IL-4 was compared with intermediate and high IL-4 groups.
ap < 0.05.
bp < 0.01.
FigUre 2 | high interleukin (il)-4 concentration promotes a mature dendritic cells (Dcs) phenotype from precursor cells. DCs were propagation under 
various concentration of IL-4 as described in Section “Materials and Methods,” and then the cells were harvested for costimulatory molecules expression analysis by 
flow cytometry. (a) The surface expression of CD80, CD86, and MHC-II on the bone marrow-derived DCs (BMDCs) differentiated from IL-4 (2, 5, and 10 ng/ml, 
respectively) were plotted in histograms. (B) CD80, CD86, and CD83 expressions on monocyte-derived DCs (MoDCs) generated from IL-4 (5, 10, and 20 ng/ml, 
respectively) were detected. (c,D) Pinocytotic activities of BMDCs and MoDCs, which are generated from various IL-4 concentrations as shown above, were 
represented by mean fluorescence intensity of cells incubated with FITC-dextran. The plots shown were obtained from CD11c+ gate. Data are representative of 
three independent experiments.
4
Tu et al. IL-4 Regulates CD103+ DCs Differentiation
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 214
(Figures 2C,D; Table 1), which is a character of immature DCs. 
These data suggest a crucial role of IL-4 in the development of 
DCs from precursor cells.
il-4 Promotes T cells activation through 
regulating iDO expression in Dcs
Interestingly, previous studies have demonstrated that high con-
centration of IL-4 augmented IL-12 production and diminished 
IL-10 expression in DCs, which led to a Th1 immune response 
(17, 18). IDO secreted by DCs can degrade the amino acid 
tryptophan, which is essential for T cells proliferation, and exert 
an inhibitory role in T cells activation (23). However, the effect 
FigUre 4 | interleukin (il)-4 affects the capability of dendritic cells (Dcs) in T cell activation through regulating indoleamine 2,3-dioxygenase (iDO) 
activity. Bone marrow-derived DCs (BMDCs) and monocyte-derived DCs (MoDCs) were generated under various concentration of IL-4 (nanograms per milliliter). 
Then the BMDCs and MoDCs were cocultured with CFSE-labeled naïve CD4+ T cells from normal C57/BL6 mice or healthy volunteers, respectively, with or without 
the presence of IDO inhibitor (25 μM). After 5 days, the cells were harvested and analyzed by flow cytometry. (a,B) The CD4+ T cells proliferation was evaluated by 
cell division. Results are represented as mean ± SD. (c,D) The CD4+ T cells were also collected and analyzed for type 1 cytokines IFN-γ expression by flow 
cytometry. Results are represented as mean ± SD. The data shown are representative one of the three separate experiments.
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of IL-4 on IDO expression in DCs was not clearly elucidated. 
In this study, we observed that IDO expressions in DCs were 
significantly decreased under the high concentration of IL-4 
when compared with low IL-4 (Figure 3). To further explore the 
role of IDO+ DCs regulated by IL-4 in T cell immune response, 
the DCs were cocultured with T cells, and the proliferation was 
investigated. Flow cytometry analysis revealed a high proportion 
of dividing T cells in DCs differentiated under high-dose IL-4. 
Conversely, BMDCs and MoDCs differentiated under low-dose 
IL-4 exerts a gentle action on T cells division (Figures 4A,B). As 
expected, the neutralization of IDO enzymic activity of low-dose 
educated DCs by 1-MT led to a markedly enhanced capability in 
T cells proliferation (Figure 4A). What’s more, when compared 
with that in high IL-4 group, low-dose IL-4-generated DCs 
showed a weaker effect on priming naïve T cells to Th1 expansion. 
This effect was also obviously enhanced by IDO inhibitor 1-MT 
(Figures 4C,D). These results revealed that IL-4 can regulate IDO 
expression and suggested that an IL-4-dominated inflammatory 
cytokine milieu was instructive for immune responses activation 
through regulating DCs functions.
il-4 retards cD103+ Dcs Differentiation
Studies have shown that CD103+ DCs in the gut showed a high 
IDO expression (19). In line with increased IL-4 expression in 
IBDs described by other reports (12, 30), we also observed an 
increased IL-4 expression in DSS-induced colitis (Figure  5A). 
Besides, the CD103+ DCs subpopulation was also deceased 
in colitis mice (Figure  5B). Although above data suggested 
IDO expression can be regulated by IL-4 and loss of CD103+ 
DCs during colonic inflammation, the role of elevated IL-4 in 
the development of gut-associated tolerogenic CD103+ DCs 
remains unknown. To our expectation, high concentration 
IL-4 significantly reduced CD103+ DCs proportion in BMDCs 
and MoDCs (Figure  5C). In parallel with gut CD103+ DCs, 
the IDO expression was considerably higher in CD103+ DCs 
when compared with CD103− DCs from BMDCs induced by 
IL-4 and GM-CSF ex vivo. Similarly, a higher expression of 
IDO was also observed in CD103+ DCs from human MoDCs 
(Figure 5D). These data indicated that IL-4 involved in the pro-
cess of CD103+IDO+ DCs education, suggesting that elevated 
IL-4 expression in IBDs might contribute to pathogenesis of 
colonic inflammation. However, in contrast to low expression 
of costimulatory molecules on CD103− DCs, CD103+ DCs 
highly expressed costimulatory molecules, especially in BMDCs 
(Figures  6A,B). Although costimulatory molecules commonly 
facilitated immune response, CD80 and CD86 are also essential 
for Treg cells development and proliferation in obese mice and 
humans, which revealed a protective effect on adipose inflamma-
tion (7, 8). Notably, CD103+ DCs derived from precursor cells 
in vitro displayed an immature character, as evidenced by a strong 
pinocytotic ability (Figures 6C,D).
impaired Treg cells Differentiation in Dcs 
generated in a low il-4 environment due 
to the loss of cD103+ Dcs
Numerous studies revealed that CD103+ DCs exert a critical role 
in immune tolerance through promoting Treg cells expansion in 
gut immunity, and above results showed that IL-4 affected CD103+ 
DCs induction and Treg cells in  vitro. However, the Treg cells 
expanded by DCs differentiated under various concentrations of 
IL-4 and CD103+ DCs in vitro were still elusive. The sorted naïve 
CD4+ T cells were cocultured with DCs differentiated under low 
or high IL-4 concentrations and then analyzed by flow cytometry. 
Both mouse BMDCs and human MoDCs were capable of priming 
naïve T cells to Treg cells. In contrast to DCs propagated from high-
dose IL-4, DCs differentiated at a low concentration of IL-4 exerted 
a strong preference for expanding Treg cells (Figures 7A,C). Next, 
FigUre 5 | cD103+iDO+ dendritic cells (Dcs) differentiation was affected by interleukin (il)-4. (a,B) Mesenteric lymph nodes (MLN) cells and serum were 
collected from the colitis mice after administration of DSS water or normal mice. The interleukin (IL)-4 levels in sera were detected by ELISA assay. (a). MLN cells 
were analyzed by flow cytometry for CD103+ DCs. The data are presented as the percentage of CD11c+ gate (B). The data represent mean ± SD (n = 4–6/group). 
(c,D) The differentiated bone marrow-derived DCs (BMDCs) and monocyte-derived DCs (MoDCs) from precursor cells in the presence of different IL-4 
concentrations (nanograms per milliliter), followed by flow cytometry analysis of CD103 expression (c). The expression of indoleamine 2,3-dioxygenase (IDO) in the 
subpopulation of BMDCs and MoDCs by CD103 was determined by flow cytometry. The CD11c positive gate was analyzed (D). Data are from one experiment 
representative of three. Results are represent as mean ± SD. *p < 0.05, #p < 0.01.
6
Tu et al. IL-4 Regulates CD103+ DCs Differentiation
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 214
to explore whether the low-dose IL-4-educated DCs in Treg cells 
expansion was contingent on the high propagation of CD103+ 
DCs, the CD103− DCs generated under low-dose IL-4 were 
cocultured with T cells. Expectedly, compared with total DCs gen-
erated under low dose of IL-4, CD103 DCs exhibited a significant 
diminishment of the Treg cells differentiation in both humans and 
mice experiment (Figures 7B,C). These data clearly demonstrate 
that the concentration of IL-4 present during differentiation of DC 
precursors is crucial for the CD103+ DCs development in IBDs.
DiscUssiOn
Type 2 immune response exhibits a strong preference in gut 
immunity by conferring protection against helminthic infection 
(31). Beyond that, type 2 immune response is also involved in 
the process of wound healing in the gut (32, 33). Nevertheless, 
dysregulated and overreactive Th2 immunity may lead to det-
rimental inflammation. Th2-induced fibrogenesis can lead to a 
deleterious consequence by augmenting mucosal and transmural 
fibrotic process, a prototypic manifestation of IBDs (15, 33). It 
is well known that IL-4, the core signature of Th2 responses, is 
highly expressed in certain types of inflammation and also exerts 
pleiotropic functions due to extremely broad distribution of IL-4 
receptors (10). Enormous reports have also provided evidences 
that IL-4 participates in the pathogenesis of IBDs (34, 35). 
Oxazolone-induced colitis, resembling the human UC, shows a 
bias of type 2 immune response. It is noteworthy that oxazolone-
induced colitis in mice lacking IL-4Ra or STAT6 was significantly 
FigUre 6 | The phenotype of cD103+ dendritic cells (Dcs) differentiated from precursor cells. DCs were propagation under 2 ng/ml interleukin (IL)-4 for 
bone marrow-derived DCs (BMDCs) and 5 ng/ml IL-4 for monocyte-derived DCs (MoDCs) in the presence of GM-CSF as described in Section “Materials and 
Methods,” and then the cells were harvested and analyzed by flow cytometry. (a) The surface expressions of CD80, CD86, and MHC-II on the CD103− and 
CD103+ BMDCs were detected and plotted in histograms. (B) CD80, CD86, and CD83 expressions on CD103− and CD103+ MoDCs were analyzed. (c,D) 
Pinocytotic activities of CD103− and CD103+ of BMDCs and MoDCs were represented by mean fluorescence intensity (MFI) of cells incubated with FITC-dextran. 
Data are representative of three independent experiments.
FigUre 7 | The potential of dendritic cells (Dcs) generated under low concentration of interleukin (il)-4 in regulatory T cells differentiation depend 
on cD103+ Dcs. BMDCs and MoDCs were generated under low (BMDC, 2 ng/ml; MoDCs, 5 ng/ml) and high (BMDC, 10 ng/ml; MoDCs, 20 ng/ml) concentration 
of IL-4 (a). The CD103− DCs were sorted from DCs which generated under low concentration of IL-4 (B). Then these DCs were subjected to cocultured with naïve 
CD4+ T cells for 5 days in the presence of anti-CD3 (0.5 μg/ml), respectively. Then the cells were collected for analyzing CD4+CD25+Foxp3+ differentiation by flow 
cytometry. Results are represented as means ± SD (c). The data shown are representative of one of the three separate experiments. *p < 0.05, #p < 0.01.
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improved (36, 37). Consistently, blockade of IL-4 cytokine 
activity by IL-4 antibody administration exhibited a protective 
effect in oxazolone-induced colitis (38, 39). In accordance with 
previous studies (12, 15), our data also showed that there was 
an increased IL-4 level in DSS-induced colitis (data not shown). 
Furthermore, the importance of IL-4 in DSS-induced colitis model 
was confirmed by using IL-4 knockout mice (40). However, the 
mechanism of IL-4 in colitis remains to be defined. Robust data 
have indicated a crucial role for DCs in the pathogenesis (41). In 
this study, we demonstrate a novel function of IL-4 in regulating 
the CD103+ DCs differentiation. CD103+ DCs, a critical DCs 
subset in the gut immune homeostasis and the primary source of 
IDO, play a preponderant role in IBDs through promoting Treg 
cells differentiation (42). Our previous study also demonstrated 
that the administration of rIL-33 favors Treg cells function 
through upregulation of CD103+ DCs in animal experimental 
colitis (24). A tendency of decreased number of Treg cells was 
observed here (data not shown). The number of Treg cells was 
not significantly changed, which might be due to the Treg cells 
differentiation affected by many factors in vivo. However, their 
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DCs conversion was impaired in the development of IBDs (20), a 
question remained to be addressed is that whether the epithelium 
injury is the cause or a consequence of CD103+ DCs loss.
Heretofore, enormous progress has been made in understand-
ing the role of IL-4 in the pathogenesis of IBDs, and the precise 
mechanism of this cytokine in IBDs is still unclear and needs 
to be further studied (33). Until now, many cytokines exhibit 
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lowed by LPS stimulation suppressed alloreactive T cells during 
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of IL-12 and low IL-10 DCs (18). Although IL-4 acts a crucial role 
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In conclusion, we provided novel insights into the loss of 
CD103+ DCs in IBDs, which might be a result of elevated IL-4 
expression. Beyond that, our study supported a new relationship 
among IL-4, CD103+ DCs, and epithelial cells in the pathogen-
esis of IBDs: in the initial phase of colitis, abnormal Th2 type 
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to loss of tolerogenic CD103+ DC and Treg cells dysfunction. 
Furthermore, the injury of epithelium resulted from abnormal 
immune response, in turn, worsens the abnormal immune 
response due to impaired capability to induce CD103+ DCs 
conversion. Therefore, IL-4 plays a crucial in the development 
of colitis.
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